A randomised placebo-controlled trial of testosterone undecanoate in obese men as adjuvant therapy for a weight loss program

Phase 3

Completed

• Conditions: Obstructive Sleep Apnea (OSA); Respiratory - Sleep apnoea; Diet and Nutrition - Obesity

• Registration Number: ACTRN12606000404527
• Lead Sponsor: The Woolcock Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-09-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

No significant uncontrolled medical problems.

Exclusion Criteria

Severe OSA ((minimum oxygen saturation < 65% or RDI > 80) requiring immediate treatment due to severity or increased associated risk (eg Transport worker), Use of drugs that alter androgen action, Contraindications to testosterone therapy, Desire for paternity within the next 12 months, Participation in sports that ban testosterone and require drug monitoring, Psychiatric disorders or drug abuse unless well controlled,Chronic medical conditions likely to interfere with or influence study treatment or safety unless well controlled.

Study & Design

• Study Type: Interventional
• Study Design: Not specified